Multiple sclerosis genetics

Handbook of Clinical Neurology

Volumn 122, Issue , 2014, Pages 193-209

  Cree, Bruce A C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

1501; Chromosome 6; Complex inheritance; Disease course; DRB1; Genetic basis; Genetics; Genome wide association; HLA; Linkage; Major histocompatibility complex; Relapsing remitting; Twin studies

Indexed keywords

ANIMAL; ARTICLE; CHROMOSOME 6; COMPLEX INHERITANCE; DISEASE COURSE; DRB1*1501; GENETIC ASSOCIATION; GENETIC BASIS; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; GENOME-WIDE ASSOCIATION; HLA SYSTEM; HUMAN; IMMUNOLOGY; LINKAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM; METHODOLOGY; MULTIPLE SCLEROSIS; PEDIGREE; RELAPSING REMITTING; RISK FACTOR; TWINS;

CHROMOSOME 6; COMPLEX INHERITANCE; DISEASE COURSE; DRB1*1501; GENETIC BASIS; GENETICS; GENOME-WIDE ASSOCIATION; HLA; LINKAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; RELAPSING REMITTING; TWIN STUDIES;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MULTIPLE SCLEROSIS; PEDIGREE; RISK FACTORS;

EID: 84893455468     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52001-2.00009-1     Document Type: Chapter

References (135)

1. Akesson E., Oturai A., Berg J., et al. A genome-wide screen for linkage in Nordic sib-pairs with multiple sclerosis. Genes Immun 2002, 3:279-285.
2. Allcock R.J., Atrazhev A.M., Beck S., et al. The MHC haplotype project: a resource for HLA-linked association studies. Tissue Antigens 2002, 59:520-521.
3. Alter M., Kahana E., Zilber N., et al. Multiple sclerosis frequency in Israel's diverse populations. Neurology 2006, 66:1061-1066.
4. Australia and New Zealand Multiple Sclerosis Genetics Consortium Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 2009, 41:824-828.
5. Ban M., Stewart G.J., Bennetts B.H., et al. A genome screen for linkage in Australian sibling-pairs with multiple sclerosis. Genes Immun 2002, 3:464-469.
6. Ban M., Goris A., Lorentzen A.R., et al. Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum Genet 2009, 17:1309-1313.
7. Baranzini S.E., Wang J., Gibson R.A., et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009, 18:767-778.
8. Baranzini S.E., Mudge J., van Velkinburgh J.C., et al. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 2010, 464:1351-1356.
9. Barcellos L.F., Oksenberg J.R., Begovich A.B., et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003, 72:710-716.
10. Barcellos L.F., Sawcer S., Ramsay P.P., et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006, 15:2813-2824.
11. Bernstein B.E., Birney E., Dunham I., et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489:57-74. ENCODE Project Consortium.
12. Bertrams J., Kuwert E. HL-A antigen frequencies in multiple sclerosis. Significant increase of HL-A3, HL-A10 and W5, and decrease of HL-A12. Eur Neurol 1972, 7:74-78.
13. Bertrams J., Kuwert E., Liedtke U. HL-A antigens and multiple sclerosis. Tissue Antigens 1972, 2:405-408.
14. Botstein D., White R.L., Skolnick M., et al. Construction of a genetic linkage map in man using restriction fragment length polymorphisms. Am J Hum Genet 1980, 32:314-331.
15. Brassat D., Salemi G., Barcellos L.F., et al. The HLA locus and multiple sclerosis in Sicily. Neurology 2005, 64:361-363.
16. Brynedal B., Duvefelt K., Jonasdottir G., et al. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS One 2007, 2:e664.
17. Burton P.R., Clayton D.G., Cardon L.R., et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007, 39:1329-1337. Wellcome Trust Case Control Consortium; Australo-Anglo-American Spondylitis Consortium (TASC).
18. Caillier S.J., Briggs F., Cree B.A., et al. Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. J Immunol 2008, 181:5473-5480.
19. Carton H., Vlietinck R., Debruyne J., et al. Risks of multiple sclerosis in relatives of patients in Flanders, Belgium. J Neurol Neurosurg Psychiatry 1997, 62:329-333.
20. Celius E.G., Harbo H.F., Egeland T., et al. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci 2000, 178:132-135.
21. Chao M.J., Barnardo M.C., Lui G.Z., et al. Transmission of class I/II multi-locus MHC haplotypes and multiple sclerosis susceptibility: accounting for linkage disequilibrium. Hum Mol Genet 2007, 16:1951-1958.
22. Cohen D., Cohen O., Marcadet A., et al. Class II HLA-DC beta-chain DNA restriction fragments differentiate among HLA-DR2 individuals in insulin-dependent diabetes and multiple sclerosis. Proc Natl Acad Sci U S A 1984, 81:1774-1778.
23. Comabella M., Martin R. Genomics in multiple sclerosis - current state and future directions. J Neuroimmunol 2007, 187:1-8.
24. Compston A. Genetic epidemiology of multiple sclerosis. J Neurol Neurosurg Psychiatry 1997, 62:553-561.
25. Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359:1221-1231.
26. Compston D.A., Batchelor J.R., McDonald W.I. B-lymphocyte alloantigens associated with multiple sclerosis. Lancet 1976, 308:1261-1265.
27. Coraddu F., Sawcer S., D'Alfonso S., et al. A genome screen for multiple sclerosis in Sardinian multiplex families. Eur J Hum Genet 2001, 9:621-626.
28. Cree B.A., Reich D.E., Khan O., et al. Modification of multiple sclerosis phenotypes by African ancestry at HLA. Arch Neurol 2009, 66:226-233.
29. Cree B.A., Rioux J.D., McCauley J.L., et al. A major histocompatibility class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01. PLoS One 2010, 5:e11296.
30. Curtius F.S.H. Multiple sklerose und erbanlage. Z Gesamte Neurol Psychiatrie 1938, 160:226-245.
31. Davenport C.B. Multiple sclerosis from the standpoint of geographic distribution and race. Arch Neurol 1922, 8:51-58.
32. de Bakker P.I., McVean G., Sabeti P.C., et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet 2006, 38:1166-1172.
33. De Jager P.L., Jia X., Wang J., et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009, 41:776-782.
34. Dean G., McLoughlin H., Brady R., et al. Multiple sclerosis among immigrants in Greater London. Br Med J 1976, 1:861-864.
35. Detels R., Visscher B.R., Malmgren R.M., et al. Evidence for lower susceptibility to multiple sclerosis in Japanese-Americans. Am J Epidemiol 1977, 105:303-310.
36. Djebali S., Davis C.A., Merkel A., et al. Landscape of transcription in human cells. Nature 2012, 489:101-108.
37. Dyment D.A., Willer C.J., Scott B., et al. Genetic susceptibility to MS: a second stage analysis in Canadian MS families. Neurogenetics 2001, 3:145-151.
38. Dyment D.A., Ebers G.C., Sadovnick A.D. Genetics of multiple sclerosis. Lancet Neurol 2004, 3:104-110.
39. Dyment D.A., Sadovnick A.D., Willer C.J., et al. An extended genome scan in 442 Canadian multiple sclerosis-affected sibships: a report from the Canadian Collaborative Study Group. Hum Mol Genet 2004, 13:1005-1015.
40. Dyment D.A., Herrera B.M., Cader M.Z., et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet 2005, 14:2019-2026.
41. Dyment D.A., Cader M.Z., Chao M.J., et al. Exome sequencing identifies a novel multiple sclerosis susceptibility variant in the TYK2 gene. Neurology 2012, 79:406-411.
42. Ebers G.C., Bulman D.E., Sadovnick A.D., et al. A population-based study of multiple sclerosis in twins. N Engl J Med 1986, 315:1638-1642.
43. Ebers G.C., Sadovnick A.D., Risch N.J. A genetic basis for familial aggregation in multiple sclerosis. Nature 1995, 377:150-151. Canadian Collaborative Study Group.
44. Ebers G.C., Kukay K., Bulman D.E., et al. A full genome search in multiple sclerosis. Nat Genet 1996, 13:472-476.
45. Ebers G.C., Yee I.M., Sadovnick A.D., et al. Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Canadian Collaborative Study Group. Ann Neurol 2000, 48:927-931.
46. Ebers G.C., Sadovnick A.D., Dyment D.A., et al. Parent-of-origin effect in multiple sclerosis: observations in half-siblings. Lancet 2004, 363:1773-1774.
47. Eichorst H. Über infantile und heriditare multiple Sklerose. Virchow's Arch Pathol Anat Berl 1896, 146:173-192.
48. Eraksoy M., Hensiek A., Kurtuncu M., et al. A genome screen for linkage disequilibrium in Turkish multiple sclerosis. J Neuroimmunol 2003, 143:129-132.
49. GAMES; Transatlantic Multiple Sclerosis Genetics Cooperative A meta-analysis of whole genome linkage screens in multiple sclerosis. J Neuroimmunol 2003, 143:39-46.
50. Gelfand J.M., Cree B.A., McElroy J., et al. Vitamin D in African Americans with multiple sclerosis. Neurology 2011, 76:1824-1830.
51. Gowers W.R. A manual of diseases of the nervous system 1893, Churchill, London. 2nd edn.
52. Gregory S.G., Schmidt S., Seth P., et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007, 39:1083-1091.
53. Guo S.W. Sibling recurrence risk ratio as a measure of genetic effect: caveat emptor!. Am J Hum Genet 2002, 70:818-819.
54. Hader W.J. Prevalence of multiple sclerosis in Saskatoon. Can Med Assoc J 1982, 127:295-297.
55. Hafler D.A., Compston A., Sawcer S., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007, 357:851-862. International Multiple Sclerosis Genetics Consortium.
56. Haines J.L., Ter-Minassian M., Bazyk A., et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet 1996, 13:469-471.
57. Hansen T., Skytthe A., Stenager E., et al. Risk for multiple sclerosis in dizygotic and monozygotic twins. Mult Scler 2005, 11:500-503.
58. Healy B.C., Liguori M., Tran D., et al. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology 2010, 75:634-640.
59. Hensiek A.E., Sawcer S.J., Smilie B., et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 2002, 72:184-187.
60. Hensiek A.E., Roxburgh R., Smilie B., et al. Updated results of the United Kingdom linkage-based genome screen in multiple sclerosis. J Neuroimmunol 2003, 143:25-30.
61. Horton R., Gibson R., Coggill P., et al. Variation analysis and gene annotation of eight MHC haplotypes: the MHC Haplotype Project. Immunogenetics 2008, 60:1-18.
62. IMSGC, Briggs F.B., Shao X., Goldstein B.A., et al. Genome-wide association study of severity in multiple sclerosis. Genes Immun 2011, 12:615-625.
63. International HapMap Consortium The International HapMap Project. Nature 2003, 426:789-796.
64. International Human Genome Sequencing Consortium Finishing the euchromatic sequence of the human genome. Nature 2004, 431:931-945.
65. Islam T., Gauderman W.J., Cozen W., et al. Differential twin concordance for multiple sclerosis by latitude of birthplace. Ann Neurol 2006, 60:56-64.
66. Islam T., Gauderman W.J., Cozen W., et al. Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 2007, 69:381-388.
67. Jakkula E., Leppä V., Sulonen A.M., et al. Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am J Hum Genet 2010, 86:285-291.
68. Jersild C., Svejgaard A., Fog T. HL-A antigens and multiple sclerosis. Lancet 1972, 1:1240-1241.
69. Jersild C., Fog T., Hansen G.S., et al. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973, 2:1221-1225.
70. Johnson B.A., Wang J., Taylor E.M., et al. Multiple sclerosis susceptibility alleles in African Americans. Genes Immun 2010, 11:343-350.
71. Kenealy S.J., Babron M.C., Bradford Y., et al. A second-generation genomic screen for multiple sclerosis. Am J Hum Genet 2004, 75:1070-1078.
72. Kuokkanen S., Gschwend M., Rioux J.D., et al. Genomewide scan of multiple sclerosis in Finnish multiplex families. Am J Hum Genet 1997, 61:1379-1387.
73. Kurtzke J.F., Beebe G.W., Nagler B., et al. Studies on the natural history of multiple sclerosis - 8. Early prognostic features of the later course of the illness. J Chron Dis 1977, 30:819-830.
74. Kurtzke J.F., Beebe G.W., Norman J.E. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology 1979, 29:1228-1235.
75. Lundmark F., Duvefelt K., Hillert J. Genetic association analysis of the interleukin 7 gene (IL7) in multiple sclerosis. J Neuroimmunol 2007, 192:171-173.
76. Lundmark F., Duvefelt K., Iacobaeus E., et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007, 39:1108-1113.
77. Marrosu M.G., Muntoni F., Murru M.R., et al. Sardinian multiple sclerosis is associated with HLA-DR4: a serologic and molecular analysis. Neurology 1988, 38:1749-1753.
78. Marrosu M.G., Murru M.R., Costa G., et al. DRB1-DQA1-DQB1 loci and multiple sclerosis predisposition in the Sardinian population. Hum Mol Genet 1998, 7:1235-1237.
79. Marrosu M.G., Murru R., Murru M.R., et al. Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia. Hum Mol Genet 2001, 10:2907-2916.
80. Masterman T., Ligers A., Olsson T., et al. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 2000, 48:211-219.
81. Matesanz F., Fedetz M., Collado-Romero M., et al. Allelic expression and interleukin-2 polymorphisms in multiple sclerosis. J Neuroimmunol 2001, 119:101-105.
82. McAlpine D. The problem of disseminated sclerosis. Brain 1946, 69:233-250.
83. Menge T., Lalive P.H., von Büdingen H.C., et al. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy Clin Immunol 2005, 116:453-459.
84. Merikangas K.R., Risch N. Genomic priorities and public health. Science 2003, 302:599-601.
85. Mero I.L., Lorentzen A.R., Ban M., et al. A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. Eur J Hum Genet 2010, 18:502-504.
86. Millar J.H., Allison R.S. Familial incidence of disseminated sclerosis in Northern Ireland. Ulster Med J 1954, 23(Suppl. 2):29-92.
87. Miretti M.M., Walsh E.C., Ke X., et al. A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms. Am J Hum Genet 2005, 76:634-646.
88. Mowry E.M., Krupp L.B., Milazzo M., et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010, 67:618-624.
89. Mumford C.J., Wood N.W., Kellar-Wood H., et al. The British Isles survey of multiple sclerosis in twins. Neurology 1994, 44:11-15.
90. Munger K.L., Levin L.I., Hollis B.W., et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
91. Naito S., Namerow N., Mickey M.R., et al. Multiple sclerosis: association with HL-A3. Tissue Antigens 1972, 2:1-4.
92. Nielsen N.M., Westergaard T., Rostgaard K., et al. Familial risk of multiple sclerosis: a nationwide cohort study. Am J Epidemiol 2005, 162:774-778.
93. Nischwitz S., Cepok S., Kroner A., et al. Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis. J Neuroimmunol 2010, 227:162-166.
94. Oger J.F., Arnason B.G., Wray S.H., et al. A study of B and T cells in multiple sclerosis. Neurology 1975, 25:444-447.
95. Oksenberg J.R., Barcellos L.F., Cree B.A., et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004, 74:160-167.
96. Okuda D.T., Srinivasan R., Oksenberg J.R., et al. Genotype-phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 2009, 132:250-259.
97. Patsopoulos N.A., Esposito F., Reischl J., et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol 2011, 70:897-912. Bayer Pharma MS Genetics Working Group; Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist; ANZgene Consortium; GeneMSA; International Multiple Sclerosis Genetics Consortium,.
98. Peltonen L., McKusick V.A. Genomics and medicine. Dissecting human disease in the postgenomic era. Science 2001, 291:1224-1229.
99. Pratt R.T., Compston N.D., McAlpine D. The familial incidence of disseminated sclerosis and its significance. Brain 1951, 74:191-232.
100. Pugliatti M., Sotgiu S., Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002, 104:182-191.
101. Ramagopalan S.V., Maugeri N.J., Handunnetthi L., et al. Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 2009, 5:e1000369.
102. Ramagopalan S.V., Heger A., Berlanga A.J., et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res 2010, 20:1352-1360.
103. Ramagopalan S.V., Dyment D.A., Cader M.Z., et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann Neurol 2011, 70:881-886.
104. Ramagopalan S.V., Handel A.E., Giovannoni G., et al. Relationship of UV exposure to prevalence of multiple sclerosis in England. Neurology 2011, 76:1410-1414.
105. Rioux J.D., Goyette P., Vyse T.J., et al. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci U S A 2009, 106:18680-18685. International MHC and Autoimmunity Genetics Network.
106. Risch N. Linkage strategies for genetically complex traits. I. Multilocus models. Am J Hum Genet 1990, 46:222-228.
107. Risch N., Merikangas K. The future of genetic studies of complex human diseases. Science 1996, 273:1516-1517.
108. Ristori G., Cannoni S., Stazi M.A., et al. Multiple sclerosis in twins from continental Italy and Sardinia: a nationwide study. Ann Neurol 2006, 59:27-34.
109. Robertson N.P., Fraser M., Deans J., et al. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain 1996, 119:449-455.
110. Robertson N.P., O'Riordan J.I., Chataway J., et al. Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis. Lancet 1997, 349:1587-1590.
111. Romero-Pinel L., Pujal J.M., Martínez-Yélamos S., et al. HLA-DRB1: genetic susceptibility and disability progression in a Spanish multiple sclerosis population. Eur J Neurol 2011, 18:337-342.
112. Rubio J.P., Stankovich J., Field J., et al. Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians. Genes Immun 2008, 9:624-630.
113. Sadovnick A.D., Baird P.A., Ward R.H. Multiple sclerosis: updated risks for relatives. Am J Med Genet 1988, 29:533-541.
114. Sadovnick A.D., Ebers G.C., Dyment D.A., et al. Evidence for genetic basis of multiple sclerosis. Lancet 1996, 347:1728-1730.
115. Sanna S., Pitzalis M., Zoledziewska M., et al. Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis. Nat Genet 2010, 42:495-497.
116. Sawcer S. The complex genetics of multiple sclerosis: pitfalls and prospects. Brain 2008, 131:3118-3131.
117. Sawcer S. Bayes factors in complex genetics. Eur J Hum Genet 2010, 18:746-750.
118. Sawcer S., Jones H.B., Feakes R., et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996, 13:464-468.
119. Sawcer S.J., Maranian M., Singlehurst S., et al. Enhancing linkage analysis of complex disorders: an evaluation of high-density genotyping. Hum Mol Genet 2004, 13:1943-1949.
120. Sawcer S., Ban M., Maranian M., et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 2005, 77:454-467.
121. Sawcer S., Hellenthal G., Pirinen M., et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219. International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2.
122. Simpson S., Taylor B., Blizzard L., et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010, 68:193-203.
123. Smestad C., Brynedal B., Jonasdottir G., et al. The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur J Neurol 2007, 14:835-840.
124. Smestad C., Sandvik L., Holmoy T., et al. Marked differences in prevalence of multiple sclerosis between ethnic groups in Oslo, Norway. J Neurol 2008, 255:49-55.
125. Smolders J., Menheere P., Kessels A., et al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008, 14:1220-1224.
126. Soilu-Hänninen M., Laaksonen M., Laitinen I., et al. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008, 79:152-157.
127. Stewart C.A., Horton R., Allcock R.J., et al. Complete MHC haplotype sequencing for common disease gene mapping. Genome Res 2004, 14:1176-1187.
128. Svenson L.W., Woodhead S.E., Platt G.H. Regional variations in the prevalence rates of multiple sclerosis in the province of Alberta, Canada. Neuroepidemiology 1994, 13:8-13.
129. Terasaki P.I., Park M.S., Opelz G., et al. Multiple sclerosis and high incidence of a B lymphocyte antigen. Science 1976, 193:1245-1247.
130. Wallin M.T., Page W.F., Kurtzke J.F. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann Neurol 2004, 55:65-71.
131. Weber J.L., May P.E. Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet 1989, 44:388-396.
132. Weber F., Fontaine B., Cournu-Rebeix I., et al. IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun 2008, 9:259-263.
133. Willer C.J., Dyment D.A., Risch N.J., et al. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A 2003, 100:12877-12882.
134. Winchester R., Ebers G., Fu S.M., et al. B-cell alloantigen Ag 7a in multiple sclerosis. Lancet 1975, 2:814.
135. Yeo T.W., De Jager P.L., Gregory S.G., et al. A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann Neurol 2007, 61:228-236.